Resistant dermatomyositis complicated by tubercular myositis and successfully treated with rituximab

Resistant dermatomyositis complicated by tubercular myositis and successfully treated with rituximab

Sir, B-cell depleting monoclonal antibody rituximab (RTX) has been shown to be effective in patients with refractory dermatomyositis (DM). Magnetic resonance imaging (MRI) of the left leg revealed acute myositis and subcutaneous fluid collection in the areas mentioned [Figure 1]. B-cell driven respo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology India 2011-03, Vol.59 (2), p.306
Hauptverfasser: Jois, Ramesh, Vasudevan, Nikhila, Srinivasan, Pradeep, Mehta, Ravindra
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Care and treatment
Case studies
Complications and side effects
Dermatomyositis
Dermatomyositis - complications
Dermatomyositis - therapy
Diagnosis
Drug therapy
Female
Humans
Immunotherapy
Medical treatment
Patient outcomes
Risk factors
Rituximab
Treatment Outcome
Tuberculosis
Tuberculosis - complications
Tuberculosis - therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sir, B-cell depleting monoclonal antibody rituximab (RTX) has been shown to be effective in patients with refractory dermatomyositis (DM). Magnetic resonance imaging (MRI) of the left leg revealed acute myositis and subcutaneous fluid collection in the areas mentioned [Figure 1]. B-cell driven response with clonal expansion, isotype switch ultimately causing altered plasma cell maturation has been observed.
ISSN:0028-3886
1998-4022
DOI:10.4103/0028-3886.79163